NMN vs NR: What the Human Trials Show

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are the two oral NAD+ precursors with the most human data behind them. (If you're still untangling how a precursor differs from the NAD+ molecule itself, start with NMN vs NAD+ — what's the difference; this page assumes you've got that part.) They're often pitched as rivals, but the more useful framing is: both reliably raise NAD+, and both have only modest, outcome-specific human benefits. Here's what the actual trials show, side by side.

Common ground: both raise NAD+

Start with what's settled. Oral NMN raises blood NAD+ in a dose-dependent way and is well tolerated in healthy middle-aged adults ¹. A pharmaceutical-grade NMN (MIB-626) reliably increased circulating NAD+ and its metabolome — clean target engagement ². On the NR side, chronic supplementation is well tolerated and elevates NAD+ in healthy middle-aged and older adults ³. So neither wins on the basic biochemistry: both do the one thing they're designed to do. The interesting question is what happens downstream.

The NMN evidence

NMN's most famous human result is a placebo-controlled trial reporting improved muscle insulin sensitivity in prediabetic women ⁴. But two caveats matter. First, the effect was narrow — weight and most metabolic markers were unchanged. Second, the finding was publicly contested by other researchers who questioned its strength and interpretation ⁵. So treat it as a contested, narrow signal rather than a settled benefit.

Beyond insulin sensitivity, NMN trials show small, scattered functional signals. In older adults, NMN raised blood NAD+ and was associated with maintained walking speed and improved self-reported sleep quality — effects that were modest and partly subjective ⁶. Those are the kinds of results that are easy to over-sell: real enough to publish, small enough that they shouldn't anchor a purchase decision.

The NR evidence

NR's strongest selling point is its safety and target-engagement record, which is excellent — chronic dosing reliably raises NAD+ and is well tolerated ³. But NR also produced the literature's clearest "biochemistry-without-function" result: in aged human muscle, NR augmented the NAD+ metabolome and anti-inflammatory signatures yet did not improve bioenergetics or physical performance ⁷.

NR does have one concrete functional win. In the NICE randomized trial in peripheral artery disease, six months of NR produced a small but significant improvement in 6-minute walking distance (about +17.6 m between groups), larger among adherent participants ⁸. That's a modest, specific benefit in a specific patient population. On cognition, though, NR disappointed: in older adults with mild cognitive impairment it raised blood NAD+ about 2.6-fold but left neurocognitive scores unchanged ⁹.

So which is better?

Neither is a clear winner, because the honest comparison is "modest vs modest." NMN has the (contested) insulin-sensitivity signal and some soft walking/sleep results; NR has a clean safety record, a small walking benefit in PAD, and a clear cognitive null. Both reliably raise NAD+; both leave most hoped-for clinical benefits unproven or inconsistent. Choosing between them on the basis of dramatic efficacy differences isn't supported by the data — the differences are small and outcome-specific.

It's also worth resisting the urge to read too much into any single head-to-head detail. The two precursors have not been compared against each other in a large, well-powered trial measuring the outcomes most people care about, so claims that one is decisively superior tend to over-interpret small studies run in different populations, with different doses, over different durations. When you line the trials up, the most defensible reading is that NMN and NR are roughly interchangeable in what they reliably deliver — a real rise in NAD+ — and roughly equal in what they don't reliably deliver, which is most of the felt benefits.

A practical implication: if you decide to try a precursor, factors like third-party purity testing, dose transparency, and cost are at least as reasonable a basis for choosing as the thin efficacy gap between the two molecules. On the NR side, the most-studied branded option is Tru Niagen — we put its trial record under the microscope in our Tru Niagen review and weigh it against its pricier rival in Tru Niagen vs Elysium Basis. One non-evidence factor that has nudged some buyers toward NR is regulatory: NMN went through a turbulent FDA exclusion and Amazon delisting before being declared lawful again in 2025 — the full story is in why people stop taking NMN and the FDA NMN saga.

A note on injectable and nasal NAD+

If you're comparing forms, keep one thing front of mind: this entire comparison is about oral precursors. There is no rigorous human RCT of injectable, IV, or nasal NAD+. So "NMN vs NR" is a real, evidence-based question; "is the injectable better than oral?" is not yet an answerable one, because the non-oral routes have no controlled human trials behind them. The same caution applies to products that swallow NAD+ itself in fat-bubble form — we examine whether liposomal NAD+ actually absorbs orally and find the bioavailability claims are mostly brand-made.

Bottom line

Both NMN and NR are safe, well-tolerated, and reliably raise NAD+. Their downstream benefits are modest and outcome-specific, and no clean efficacy gap separates them. For the broader context — energy, focus, and longevity claims — see our pillar guide: NAD+ therapy: the evidence. And to see where NMN and NR sit against niacin, nicotinamide, liposomal NAD+ and IV in one evidence-tiered ranking, read the best NAD+ supplements, rated by evidence. And for the next-generation precursor newly added to the conversation, see our review of trigonelline.